A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.

Andrew Yee,Jacob P. Laubach,Erica L. Campagnaro,Brea Lipe,Omar Nadeem,Craig E. Cole,Elizabeth ODonnell,Robert Schlossman,Giada Bianchi,Andrew R. Branagan,Samantha J. Shapiro,Cynthia C. Harrington,Jill N. Burke,Marilyn T. Gammon,Kathleen J. Lively,Cassandra Thorburn,Mason L. Mann,Jens Lohr,Paul G. Richardson,Noopur Raje

A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.

2018

8012Background: Elotuzumab is an approved monoclonal antibody targeting SLAMF7 on NK cells and plasma cells that enhances the activity of lenalidomide and bortezomib in multiple myeloma (MM). We st...

Keywords:

Pomalidomide
Refractory Multiple Myeloma
Dexamethasone
Pathology
Bortezomib
Phases of clinical research
Oncology
Medicine
Internal medicine
Elotuzumab
Cancer research
Multiple myeloma
SLAMF7
Lenalidomide
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations